About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Kevin Riley, Production Coordinator
Statement of Purpose
Guidelines for Authors
Rituximab for the Treatment of Refractory Rheumatoid Arthritis: New Information from Clinical Trials
The authors present new data from the DANCER and REFLEX trials on Rituxan.
Angela Singh, PharmD, Patty Ghazvini, PharmD, Marlon Honeywell, PharmD, and Phillip Treadwell, PharmD
Cost Implications of Using Unfractionated Heparin or Enoxaparin in Medical Patients at Risk for Venous Thromboembolic Events
Using “real-world” data, the authors present a comparison of costs of unfractionated heparin and a low-molecular-weight heparin (enoxaparin) in preventing thromboembolism in hospitalized patients.
Richard M. Weinberg, MD, CPE, Leo K. Lichtig, PhD, Joseph A. Caprini, MD, MS, Geno J. Merli, MD, and F. Randy Vogenberg, RPh, PhD
Dr. Goldenberg reviews rituximab (Rituxan) for rheumatoid arthritis, alglucosidase alfa (Myzozyme) for Pompe disease, and docetaxel (Taxotere) for advanced stomach cancer.
Marvin M. Goldenberg, PhD, RPh, MS
The authors review interferon beta-1b for emerging multiple sclerosis, a rotigotine patch as adjunctive therapy in Parkinson’s disease, levetiracetam for epileptic seizures, a new sumatriptan formulation and botulinum A for migraine, donepezil for severe Alzheimer’s disease, pramipexole for restless legs syndrome, atomoxetine for attention-deficit/hyperactivity disorder and comorbid Tourette
syndrome, and pregabalin for pain relief.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
A new book by Susan McCurry, PhD — When a Family Member Has Dementia — offers practical suggestions for caregivers of patients with Alzheimer’s disease.
Reviewed by David A. Casey, MD
David Nash, MD, MBA discusses Columbia University’s Department of Biomedical Informatics, a new Master’s program for teachers and researchers in medical care and drug therapy.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, focuses on how
abusive behavior and intimidation in the workplace can interfere with appropriate drug prescribing.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the FDA’s efforts to ensure improved drug safety by reorganizing itself and by
promoting workers—but is this enough?
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Dr. Marzella reviews entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection.
Nino Marzella, BS, PharmD